Industry news, page-201

Spot on @Oldpa1 ....its the same inflammatory group of interleukins, but specifically IL-6





I'm banking it will - the science revealed by IHL is certainly pointing that way - as @Chaya astutely mentioned recently IHL 675A will be potentially become 'the treatment' in relation to these inflammatory related diseases.
we can see the reasons why ... not to mention acute myocarditis and related COPD.....both inflammatory related afflictions without effective remedies / treatments atm.....as has been mentioned before, the 'standard of care' practices will potentially be rewritten with this drug candidate and the Incannex team.

again - nothing like this company on the ASX at the moment
GLA